ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone914-207-2300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees20
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
ContraFect (NASDAQ:CFRX) Frequently Asked Questions
What is ContraFect's stock symbol?
ContraFect trades on the NASDAQ under the ticker symbol "CFRX."
How were ContraFect's earnings last quarter?
ContraFect Corp (NASDAQ:CFRX) announced its quarterly earnings data on Friday, May, 10th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.26. View ContraFect's Earnings History.
When is ContraFect's next earnings date?
What price target have analysts set for CFRX?
2 brokers have issued twelve-month target prices for ContraFect's stock. Their forecasts range from $1.50 to $1.50. On average, they expect ContraFect's stock price to reach $1.50 in the next year. This suggests a possible upside of 277.8% from the stock's current price. View Analyst Price Targets for ContraFect.
What is the consensus analysts' recommendation for ContraFect?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.
Has ContraFect been receiving favorable news coverage?
Media stories about CFRX stock have trended negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ContraFect earned a news impact score of -2.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for ContraFect.
Are investors shorting ContraFect?
ContraFect saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 392,500 shares, an increase of 16.5% from the June 30th total of 337,000 shares. Based on an average daily volume of 514,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.7% of the shares of the company are sold short. View ContraFect's Current Options Chain.
Who are some of ContraFect's key competitors?
Some companies that are related to ContraFect include Northwest Biotherapeutics (NWBO), Abeona Therapeutics (ABEO), Corvus Pharmaceuticals (CRVS), CELYAD SA/ADR (CYAD), AgeX Therapeutics (AGE), Humanigen (HGEN), Scpharmaceuticals (SCPH), Sesen Bio (SESN), Tyme Technologies (TYME), MEI Pharma (MEIP), OASMIA PHARMACE/ADR (OASM), Fortress Biotech (FBIO), Entasis Therapeutics (ETTX), Aptinyx (APTX) and AVEO Pharmaceuticals (AVEO).
What other stocks do shareholders of ContraFect own?
Who are ContraFect's key executives?
ContraFect's management team includes the folowing people:
- Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
- Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
- Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
- Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
- Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)
Who are ContraFect's major shareholders?
ContraFect's stock is owned by a number of of retail and institutional investors. Top institutional investors include Oracle Investment Management Inc. (8.00%), Vanguard Group Inc. (2.30%), SG Americas Securities LLC (0.85%), Trellus Management Company LLC (0.73%), Hartwell J M Limited Partnership (0.18%) and Wells Fargo & Company MN (0.08%). View Institutional Ownership Trends for ContraFect.
Which major investors are selling ContraFect stock?
Which major investors are buying ContraFect stock?
CFRX stock was acquired by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., SG Americas Securities LLC, Trellus Management Company LLC and Hartwell J M Limited Partnership. View Insider Buying and Selling for ContraFect.
How do I buy shares of ContraFect?
Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect's stock price today?
One share of CFRX stock can currently be purchased for approximately $0.3970.
How big of a company is ContraFect?
ContraFect has a market capitalization of $31.53 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect.
What is ContraFect's official website?
How can I contact ContraFect?
ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]
MarketBeat Community Rating for ContraFect (NASDAQ CFRX)
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
